BriaCell Appoints Richard J. Berman to Board of Directors
BriaCell Therapeutics Corp. ("BriaCell" or the "Company")
, a clinical-stage biotechnology
company specializing in targeted immunotherapy for advanced breast
cancer, today announced that it has appointed Mr. Richard J.
Berman, JD, MBA, to its Board of Directors.
Mr. Berman is a highly experienced corporate
executive with over 35 years in venture capital, senior management,
and merger & acquisitions. He is a Director of a number of
public and private life science companies including Advaxis, Inc.
(NASDAQ:ADXS), a biotechnology company developing cancer
immunotherapies; Cryoport, Inc. (NASDAQ:CYRX), the leading
logistics company serving life sciences industry; BioVie Inc.
(OTCQB:BIVI), a clinical-stage company developing drug therapies
for liver disease; Immuron Limited (ASX:IMC, NASDAQ:IMRN), an
Australian biopharmaceutical company that develops and
commercializes oral polyclonal antibodies for the treatment of
inflammatory mediated and infectious diseases; and Cevolva Biotech,
Inc., a biotechnology company which developed the world’s first
non-plant derived cannabinoids.
Mr. Berman’s experience includes Director,
Catasys, Inc. (NASDAQ:CATS) (2014-2019), Chairman of Cevolva
Biotech, Inc. (2016), Chairman of MetaStat, Inc. (2014-2016),
Chairman of National Investment Managers, a company with $12
billion in pension administration assets, (2006-2011), Director
(2002-2010) and Chairman & CEO (2008-2009) of Nexmed Inc.
(currently Apricus Biosciences,Inc); Chairman & CEO (1998-2000)
and Director (1998-2012) of Internet Commerce Corporation
(currently Easylink Services). Formerly, Mr. Berman worked at
Goldman Sachs; served as Senior Vice President of Bankers Trust
Company, where he started the M&A and Leveraged Buyout
Departments, and advised on over $4 billion of M&A transactions
(completed over 300 deals). Mr. Berman served as Director of the
Stern School of Business of NYU where he earned his BS and MBA. He
obtained US and foreign law degrees from Boston College and The
Hague Academy of International Law, respectively.
"On behalf of BriaCell and our Board of
Directors, I am pleased to welcome Mr. Richard Berman to the
Board," said Mr. Jamieson Bondarenko, Chairman of the Board.
“Richard is a successful business leader with almost four decades
of experience and vast corporate relationships. He offers a great
deal of business acumen, industry knowledge, strategy, and finance
experience to the board."
"BriaCell's novel therapeutic approach has shown
promise in clinical trials and offers significant potential for
patients with breast cancer," said Mr. Berman. "I am honored to be
named to the Board of BriaCell and look forward to working with
BriaCell’s experienced Board and management teams to help develop
BriaCell’s corporate partnership pipeline and create shareholder
value," Mr. Berman added.
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and safe approaches for
the management of cancer.
BriaCell is currently conducting a Phase I/IIa
clinical trial of Bria-IMT™, BriaCell’s lead candidate, in a
Combination Study with immune checkpoint inhibitors such as
pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc.
(NYSE: MRK)]. The Combination Study is listed in ClinicalTrials.gov
BriaCell and Incyte Corporation (NASDAQ: INCY)
have formed a non-exclusive clinical trial collaboration to
evaluate the effects of combinations of novel clinical candidates.
Under the agreement, Incyte and BriaCell will be evaluating novel
combinations of compounds from Incyte’s development portfolio with
Bria-IMT™ in advanced breast cancer patients.
BriaCell is developing Bria-OTS™, an
off-the-shelf personalized immunotherapy, for advanced breast
cancer. Bria-OTS™ immunotherapy treatments are personalized to
match the patient without the need for personalized manufacturing.
Bria-OTS™, which is expected to cover over 99 percent of the
patient population, is designed to produce a potent and selective
immune response against the cancer of each patient while
eliminating the time, expense and complex manufacturing logistics
associated with other personalized immunotherapies.
For additional information on BriaCell, please
Cautionary Note Regarding Forward-Looking
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation which
involves known and unknown risks relevant to the Company in
particular and to the biotechnology and pharmaceutical industries
in general, uncertainties and other factors that may cause actual
events to differ materially from current expectation. These risks
are more fully described in the Company's public filings available
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
For further information, please
contact:BriaCell Therapeutics Corp.:Farrah
DeanManager, Corporate DevelopmentEmail: farrah@BriaCell.com Phone:
Historical Stock Chart
From Jul 2020 to Aug 2020
Historical Stock Chart
From Aug 2019 to Aug 2020